fulvestrant sandoz fulvestrant 250 mg/5 ml solution for injection in pre-filled syringe
sandoz pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: castor oil; benzyl alcohol; benzyl benzoate; ethanol - fulvestrant sandoz is indicated for the treatment of postmenopausal women with: ? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.
fulvestrant accord 250 mg inj. sol. i.m. pre-filled syr.
accord healthcare b.v. - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant
fulvestrant sandoz 250 mg inj. sol. i.m. pre-filled syr.
sandoz sa-nv - fulvestrant 250 mg/5 ml - solution for injection - 250 mg - fulvestrant 50 mg/ml - fulvestrant
fulvestrant ever pharma 250 mg inj. sol. i.m. pre-filled syr.
ever valinject gmbh - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant
fulvestrant fresenius kabi 250 mg inj. sol. i.m. pre-filled syr.
fresenius kabi sa-nv - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant
fulvestrant ever pharma 250 mg solution for injection in pre-filled syringe
ever valinject gmbh - fulvestrant - solution for injection in pre-filled syringe - 250 milligram(s) - fulvestrant
fulvestrant 250 mg s.k.
k.s.kim international (sk- pharma) ltd., israel - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapy fulvestrant is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or - with disease relapse on or after adjuvant endocrine therapy; or - disease progression on endocrine therapy combination therapy fulvestrant is indicated for the treatment of: - hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
fulvestrant-teva
teva pharma (new zealand) limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.
fulvestrant 250 mg solution for injection in pre-filled syringe
reddy holding gmbh - fulvestrant - solution for injection in pre-filled syringe - fulvestrant
fulvestrant rowex 250 mg/5 ml solution for injection in pre-filled syringe
rowex ltd - fulvestrant - solution for injection in pre-filled syringe - 250 mg/5ml - anti-estrogens; fulvestrant